How has Poly Medicure (POLYMED) been performing? We dig into revenue, profitability, valuation, and ownership trends.
Poly Medicure Revenue Trend
Poly Medicure's top line grew 22.6% to ₹1,759 Cr in FY2025, compared to ₹1,435 Cr in FY2024.
A 16.2% revenue CAGR over 10 years is hard to ignore. Poly Medicure's top line moved from ₹390 Cr to ₹1,759 Cr in that period.
At ₹1,759 Cr in annual revenue, Poly Medicure is one of the mid-sized players in the healthcare space.
Looking at the year-on-year numbers, Poly Medicure has seen 10 years of unbroken revenue growth.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,759 Cr | +22.6% |
| FY2024 | ₹1,435 Cr | +24.6% |
| FY2023 | ₹1,151 Cr | +19.8% |
| FY2022 | ₹961 Cr | +22.2% |
| FY2021 | ₹786 Cr | — |
View Poly Medicure's full 10-year revenue trend with CAGR analysis →
Poly Medicure Profitability
A 31.1% improvement in net profit took Poly Medicure's bottom line to ₹339 Cr in FY2025.
Cost discipline paid off, with net profit margin expanding to 19.2% from 18.0%.
Diluted EPS stood at ₹34.11 in FY2025, compared to ₹26.90 in FY2024.
Is Poly Medicure Undervalued
Running the numbers through the P/E Ratio model gives a fair value of ₹2,100 for Poly Medicure.
Poly Medicure shares are currently trading at ₹1,339.20.
Craytheon also calculates intrinsic value using the EPS Growth model. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹2,100 | 56.8% upside to fair value |
| EPS Growth | Upgrade | Upgrade |
See all valuation models for Poly Medicure with detailed assumptions →
Poly Medicure Shareholding Pattern
Promoter holding has remained stable at 62.4% over the past 4 quarters, indicating confidence in the company's direction.
On the foreign institutional side, the holding is 5.9% as of March 2026 — down from 11.4%.
Domestic institutional investors (DIIs) held 15.6% as of March 2026, up from 11.7% a year ago.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 62.4% | 5.9% | 15.6% | 16.1% |
| Dec 2025 | 62.4% | 9.4% | 13.8% | 14.3% |
| Sep 2025 | 62.4% | 9.8% | 13.5% | 14.3% |
| Jun 2025 | 62.4% | 11.4% | 11.7% | 14.4% |
Track quarterly shareholding changes for Poly Medicure →
Poly Medicure Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹31.92B (up 71.8% YoY from ₹18.59B).
Top categories: Property, Plant & Equipment (35.3%), Cash & ST Investments (33.4%), Receivables (11.0%).
Of the ₹31.92B in liabilities and equity, 86.6% is shareholder equity, 5.6% is interest-bearing debt, and 7.7% is operating liabilities. Over the year, debt is up 3.6% and equity is up 88.1%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 10.65B |
| Receivables | 3.50B |
| Inventories | 2.86B |
| Property, Plant & Equipment | 11.28B |
| Investments | 205.12M |
| Intangibles & Goodwill | 551.95M |
| Other Assets | 2.88B |
| Category | Value |
|---|---|
| Equity | 27.66B |
| Short-term Debt | 1.79B |
| Long-term Debt | 7.71M |
| Trade Payables | 864.19M |
| Other Liabilities | 1.60B |
Poly Medicure Key Highlights
Pulling it all together, here's what the numbers say about Poly Medicure (POLYMED) heading into the next fiscal year.
Revenue of ₹1,759 Cr in FY2025, up 22.6% year-over-year.
Long-term revenue has been compounding at 16.2% annually over 10 years.
The company is profitable, with a net margin of 19.2% and net income of ₹339 Cr.
The P/E Ratio model implies 56.8% upside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Poly Medicure.